Alnylam Expands Genetic Testing Program

Jan 05, 2018

|

This story has been updated from a previous version that incorrectly stated the development status of an Alynlam AHP drug candidate.

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced on Thursday that it has expanded a program that provides no-cost genetic testing for people at risk for certain genetic diseases to include acute hepatic porphyrias (AHPs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Featured White Papers

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Main menu